Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026)

Kiniksa Pharmaceuticals International's Cash from Operations history runs 10 years deep, the most recent figure standing at 50199000.0 for Q1 2026.

• Quarterly Cash from Operations rose 124.87% year-over-year to 50199000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165860000.0 (up 276.73% YoY) and the FY2025 annual result came in at 137985000.0, up 437.14% from the prior year.
• Cash from Operations was 50199000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, down from 53894000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 62053000.0 in Q3 2022 and bottomed at 36846000.0 in Q1 2022.
• A 5-year average of 13704764.71 and a median of 5168000.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations tumbled 113.16% — and 2025, when it jumped 1606.13%.
• Kiniksa Pharmaceuticals International's Cash from Operations stood at 11576000.0 in 2022, then jumped by 137.36% to 4325000.0 in 2023, then surged by 333.99% to 18770000.0 in 2024, then jumped by 187.13% to 53894000.0 in 2025, then declined by 6.86% to 50199000.0 in 2026.
• Business Quant data shows KNSA's Cash from Operations at 50199000.0 in Q1 2026, 53894000.0 in Q4 2025, and 33677000.0 in Q3 2025.